Studies Lend Potential Support For Xarelto Lawsuit Claims

July 05, 2016 – – TheProductLawyers.com offers insight on scholarly studies that may lend credibility to claims against Xarelto and its manufacturers, Janssen Pharmaceuticals and Bayer AG. An apparent link between an elevated risk for catastrophic hemorrhages and the new-generation blood thinner incites concern from both the public sphere and the medical community.

Granted FDA approval in 2011, Xarelto was initially embraced as a breakthrough in clot prevention treatments. Its original applications included clot prevention in those with pulmonary embolisms, deep vein thrombosis, and in patients recovering from hip and knee replacement surgeries. It was also approved to act as a stroke preventative for individuals with atrial fibrillation, a cardiac condition that increases the risk of stroke.

However, the rosy reception soon dimmed in the face of a mounting number of adverse event reports to the FDA that alleged a connection between Xarelto and strokes, clots, massive pulmonary embolisms, and uncontrollable hemorrhages. Alarmed by this potential danger, Drs. John C. Hwang and Judy H. Hun conducted a preliminary study of their own patients who were taking Xarelto at the time. They noted that at least three patients had developed “spontaneous vitreous hemorrhage,” also called eye bleeding. Further, their study revealed that the potential for these adverse events seemed elevated in those who had switched to Xarelto from a more traditional anticoagulant.

Another national study was completed which compared patients taking three blood thinners. Drawing on more than 46,000 patient histories, the study compared warfarin (39,607), Pradaxa (4,907), and Xarelto (1,649). After two years, the collated data seemed to indicate a clear connection. There was, it was noted, “as much as a 50 percent increase in the risk of gastrointestinal bleeding with dabigatran compared with warfarin or a twofold higher risk of bleeding with rivaroxaban (Xarelto) when compared with warfarin.”

The U.S. Judicial Panel on Multidistrict Litigation has combined more than 2,800 lawsuits alleging harm from Xarelto use. Cases in multidistrict litigation (MDL) 2592 will be tried in the Eastern District of Louisiana by Judge Eldon Fallon. As the court dates approach, additional cases against the drug are expected to be added to the mass litigation.

The attorneys of Banville Law, the firm behind TheProductLawyers.com, are offering complimentary consultations to anyone who suffered injury or hospitalization after a bleed while on Xarelto. For more information about this release or the Xarelto litigation call 888-997-3792.

###

Contact TheProductLawyers.com:

Banville Law
888-997-3792
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60011204